Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Yangle Li"'
Autor:
Longxiang Wu, Zhenyu Ou, Peihua Liu, Cheng Zhao, Shiyu Tong, Ruizhe Wang, Yangle Li, Junbin Yuan, Minfeng Chen, Benyi Fan, Xiongbing Zu, Yongjie Wang, Jianing Tang
Publikováno v:
Cell Communication and Signaling, Vol 21, Iss 1, Pp 1-12 (2023)
Abstract Background Prostate cancer (PC) is the most common neoplasm and is the second leading cause of cancer-related deaths in men worldwide. The Hippo tumor suppressor pathway is highly conserved in mammals and plays an important role in carcinoge
Externí odkaz:
https://doaj.org/article/dbcd77c874c14da193b3eb3f41a7c0e5
Autor:
Shiyu Tong, Zhenyu Yang, Xiongbin Zu, Yuan Li, Wei He, Yangle Li, Xiheng Hu, Cheng Zhao, Minfeng Chen, Lin Qi
Publikováno v:
World Journal of Surgical Oncology, Vol 17, Iss 1, Pp 1-7 (2019)
Abstract Objective To investigate the mortality, operation time, cystectomy time, and complications of anterior approach laparoscopic radical cystectomy (ALRC) in Asian males in comparison with posterior approach laparoscopic radical cystectomy (PLRC
Externí odkaz:
https://doaj.org/article/60552f044f4c4e418b9cc881fd99a88e
Publikováno v:
Clinical Genitourinary Cancer. 19:155-161
Purpose Primary renal neuroendocrine neoplasms (NENs) are exceedingly rare. We used the Surveillance, Epidemiology, and End Results (SEER) data to summarize clinicopathologic characteristics, treatment outcomes, and prognostic factors of primary rena
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef9c1d974ae114dfad6164c90f1781ba
https://doi.org/10.1016/j.clgc.2020.10.010
https://doi.org/10.1016/j.clgc.2020.10.010
Publikováno v:
Transl Androl Urol
Background Bladder cancer as other cancers contains multiple dynamic alterations in progression. Theoretically, large number of genes participates in cancer progression. In the present study, the interconnections of genesets defined by Gene Set Enric
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03c46f5bacda9e9f49a8765ec5f7064a
https://doi.org/10.21037/tau-20-1124
https://doi.org/10.21037/tau-20-1124
Autor:
Yinzhao, Wang, Minfeng, Chen, Yangle, Li, Cheng, Zhao, Shiyu, Tong, Yi, Cai, Ruizhe, Wang, Tailai, Zhou
Publikováno v:
Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences. 47(3)
Renal cancer is a common malignancy of the urinary system, and the partial nephrectomy is a common surgical modality for early renal cancer. 3D printing technology can create a visual three-dimensional model by using 3D digital models of the patient'
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0c6736f3f0c124e11c415aeff0e337ae
https://pubmed.ncbi.nlm.nih.gov/35545325
https://pubmed.ncbi.nlm.nih.gov/35545325
Publikováno v:
OncoTargets and Therapy. 13:11827-11838
Background Bladder cancer (BC) is one of the most common malignant tumors in the urinary system. In this study, the roles of lncRNA HCP5 (human major histocompatibility complex p5) and miR-29b-3p in human BC were investigated. Their regulations invol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::832b51bff6c0dad7e6d1bc01cae1b1ab
https://doi.org/10.2147/ott.s249770
https://doi.org/10.2147/ott.s249770
Publikováno v:
Translational Cancer Research
Background Mesoderm-specific transcript (MEST) has been demonstrated to be a proto-oncogene or anti-oncogene in various carcinomas. However, the role and mechanism of MEST in bladder cancer (BC) are still unknown. Here we aimed to explore the effect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7025bdf11477e7d45fd7f9ca32dd4ed6
https://doi.org/10.21037/tcr-20-1006
https://doi.org/10.21037/tcr-20-1006
Publikováno v:
Frontiers in Medicine
Frontiers in Medicine, Vol 8 (2021)
Frontiers in Medicine, Vol 8 (2021)
Objective: To assess the safety and efficacy of low-dose everolimus maintenance therapy for tuberous sclerosis complex-related renal angiomyolipoma (TSC-RAML) patients that had previously undergone standard-dose treatment for a minimum of 6 months.Ma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6417a45c04414c7ddb4d3c582370d60
https://doi.org/10.3389/fmed.2021.744050
https://doi.org/10.3389/fmed.2021.744050
Publikováno v:
Urologic Oncology: Seminars and Original Investigations. 40:412.e1-412.e8
Serum biomarkers are valuable tools to predict the prognosis of anticancer therapies. This study aimed to evaluate the impact of serum interleukin-6 (IL-6) level on the clinical outcome of intravesical gemcitabine (GEM) therapy in non-muscle-invasive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5daf8a49ca079ce9c20aa656534a9779
https://doi.org/10.1016/j.urolonc.2022.05.020
https://doi.org/10.1016/j.urolonc.2022.05.020
Publikováno v:
Journal of Cancer. 13(4)
Although intravesical gemcitabine (GEM) chemotherapy (IGC) can effectively reduce the recurrence risk of non-muscle invasive bladder cancer (NMIBC), the development of GEM resistance may occur and result in cancer recurrence and disease progression.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61182e712dd86c4793f41b9d216e973c
https://pubmed.ncbi.nlm.nih.gov/35281857
https://pubmed.ncbi.nlm.nih.gov/35281857